Beijing Foyou Pharma CO.,LTD

601089

CNE100005QF9

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-05-08 pm EDT			5-day change	1st Jan Change
16.1 ^CNY	+0.44%		+2.29%	-6.61%

Apr. 23	Beijing Foyou Pharma CO.,LTD Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 03	Tranche Update on Beijing Foyou Pharma CO.,LTD's Equity Buyback Plan announced on February 6, 2024.	CI

Beijing Foyou Pharma CO.,LTD Reports Earnings Results for the First Quarter Ended March 31, 2024

April 23, 2024 at 04:43 am EDT

Beijing Foyou Pharma CO.,LTD reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was CNY 802.72 million compared to CNY 819.18 million a year ago. Revenue was CNY 802.72 million compared to CNY 819.18 million a year ago.

Net income was CNY 132.58 million compared to CNY 113.71 million a year ago. Basic earnings per share from continuing operations was CNY 0.28 compared to CNY 0.24 a year ago. Diluted earnings per share from continuing operations was CNY 0.28 compared to CNY 0.24 a year ago.

Latest news about Beijing Foyou Pharma CO.,LTD

Beijing Foyou Pharma CO.,LTD Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 23	CI
Tranche Update on Beijing Foyou Pharma CO.,LTD's Equity Buyback Plan announced on February 6, 2024.	Apr. 02	CI
Beijing Foyou Pharma CO.,LTD Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 31	CI
Foyou Pharma Gets Nod for Ezetimibe and Simvastatin Tablets	Mar. 04	MT
Foyou Pharma Gets Nod for Cilostazol Tablets' Market Registration	Feb. 28	MT
Beijing Foyou Pharma CO.,LTD announces an Equity Buyback for CNY 200 million worth of its shares.	Feb. 05	CI
Beijing Foyou Pharma CO.,LTD authorizes a Buyback Plan.	Feb. 04	CI
Foyou Pharmaceutical Gets Nod for Registration of Fluvastatin Sodium Extended-Release Tablets	Dec. 20	MT
Beijing Foyou Pharmaceutical Gets Green Light to Test Clotrimazole Vaginal Tablets	Dec. 04	MT
Foyou Pharmaceutical Gets Nod for Marketing of Raw Drug Material for Anesthetic	Nov. 28	MT
Foyou Pharma Gets Nod to Market Roxadustat API	Nov. 22	MT
Beijing Foyou Pharma Gets Nod to Amend Production License	Nov. 03	MT
Beijing Foyou Pharma CO.,LTD Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-26	CI
Beijing Foyou Pharma Gets Nod to Produce Telmisartan Hydrochlorothiazide Tablets	23-10-16	MT
Beijing Foyou Pharma CO.,LTD(XSSC:601089) added to S&P Global BMI Index	23-09-18	CI
Beijing Foyou Pharma CO.,LTD Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-14	CI
Beijing Foyou Pharma CO.,LTD(SHSE:601089) added to Shanghai Stock Exchange Composite Index	23-07-03	CI
Certain A Shares of Beijing Winsunny Pharmaceutical CO.,LTD are subject to a Lock-Up Agreement Ending on 1-JUL-2023.	23-06-30	CI
Beijing Foyou Pharma CO.,LTD(SHSE:601089) added to Shanghai Stock Exchange A Share Index	23-06-30	CI
Foyou Pharma Passes Drug GMP Compliance Inspection	23-06-14	MT
Foyou Pharma Gets Certification for Diabetes Drug	23-05-18	MT
Beijing Winsunny Pharmaceutical CO.,LTD Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-28	CI
Foyou Pharma Registers Immunosuppressant Ointment in China	23-04-21	MT
Beijing Winsunny Pharmaceutical CO.,LTD Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-17	CI
Beijing Winsunny Pharmaceutical CO.,LTD Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-27	CI

Chart Beijing Foyou Pharma CO.,LTD

Duration

Period

More charts

Company Profile

Beijing Foyou Pharma Co Ltd, formerly Beijing Winsunny Pharmaceutical Co Ltd, is a China-based company mainly engaged in the research, development, production and sales of pharmaceutical preparations and medical devices. The Company's pharmaceutical preparations mainly cover the fields of cardiovascular system, chronic kidney disease, skin disease, digestive system, diabetes, mental nervous system, gynecology and others. The Company's pharmaceutical preparation products mainly include tablets, ointments, creams, gels, soft capsules, solutions, syrups, tinctures, sprays, hard capsules and others. The Company's medical device business focuses on humidification and oxygen inhalation devices, and its main products include disposable oxygen inhalation tubes and others. The Company mainly operates its businesses in the domestic and overseas markets.

Sector

Pharmaceuticals

Calendar

2024-08-12 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BEIJING FOYOU PHARMA CO.,LTD	-6.61%	1.05B
ELI LILLY AND COMPANY	+32.36%	695B
NOVO NORDISK A/S	+26.51%	568B
JOHNSON & JOHNSON	-4.40%	361B
MERCK & CO., INC.	+19.46%	330B
ABBVIE INC.	+3.50%	283B
ASTRAZENECA PLC	+16.34%	239B
NOVARTIS AG	+6.68%	204B
ROCHE HOLDING AG	-9.08%	198B
AMGEN INC.	+8.62%	168B

Other Pharmaceuticals